Glycation and biomarkers of vascular complications of diabetes

Amino Acids

Volumn 42, Issue 4, 2012, Pages 1171-1183

  Beisswenger, Paul J ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

Advanced glycation end products; Biomarkers; Clinical trials; Diabetic complications; Oxidative end products

Indexed keywords

1,2 DICARBONYL DERIVATIVE; 3 DEOXYGLUCOSONE; ADVANCED GLYCATION END PRODUCT; ANGIOTENSIN RECEPTOR ANTAGONIST; ARGININE; BIOLOGICAL MARKER; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FRUCTOSE; GLYOXAL; HEMOGLOBIN A1C; HYDROXYL RADICAL; LYSINE; METHYLGLYOXAL; PEROXIDE; SUPEROXIDE;

ALBUMINURIA; BIOASSAY; BLOOD SAMPLING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COST OF ILLNESS; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DIABETOGENESIS; DOCUMENTATION; EYE EXAMINATION; GENETIC SUSCEPTIBILITY; GLYCATION; GLYCEMIC CONTROL; HIGH RISK PATIENT; HUMAN; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; LASER COAGULATION; LIPID PEROXIDATION; LIQUID CHROMATOGRAPHY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PLASMA; PRIORITY JOURNAL; PROTEOMICS; QUADRUPOLE MASS SPECTROMETRY; QUANTITATIVE ANALYSIS; REVIEW; RISK FACTOR; RISK REDUCTION; SERUM; TISSUE INJURY; ULTRAFILTRATION; URINALYSIS; URINE LEVEL;

ANIMALS; BIOLOGICAL MARKERS; DIABETES COMPLICATIONS; GLYCOSYLATION; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS;

EID: 84862692196     PISSN: 09394451     EISSN: 14382199     Source Type: Journal    
DOI: 10.1007/s00726-010-0784-z     Document Type: Review

References (86)

1. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friedewald WT (2008) Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358(24):2545-2559 (Pubitemid 351831356)
2. Ahmed N, Argirov OK, Minhas HS, Cordeiro CA, Thornalley PJ (2002) Assay of advanced glycation endproducts (ages): surveying ages by chromatographic assay with derivatization by 6-aminoquinolyl-n-hydroxysuccinimidyl-carbamate and application to nepsilon-carboxymethyl-lysine- and nepsilon-(1-carboxyethyl) lysine-modified albumin. Biochem J 364(Pt 1):1-14 (Pubitemid 34538940)
3. Ahmed N, Babaei-Jadidi R, Howell S, Beisswenger P, Thornalley P (2005a) Degradation products of proteins damaged by glycation, oxidation and nitration in clinical type 1 diabetes. Diabetologia 48:1590-1603 (Pubitemid 41175513)
4. Ahmed N, Babaei-Jadidi R, Howell S, Thornalley P, Beisswenger P (2005b) Glycated and oxidised protein degradation products are indicators of fasting and postprandial hyperglycemia in diabetes. Diabetes Care 28:2465-2471 (Pubitemid 41384295)
5. Almuti K, Rimawi R, Spevack D, Ostfeld RJ (2006) Effects of statins beyond lipid lowering: potential for clinical benefits. Int J Cardiol 109(1):7-15 [review] [108 refs]
6. Andersen AR, Christiansen JS, Andersen JK, Kreiner S, Deckert T (1983) Diabetic nephropathy in type 1 (insulin-dependent) diabetes: an epidemiological study. Diabetologia 25(6):496-501 (Pubitemid 14200886)
7. Association AD (2007) Standards of medical care in diabetes. Diabetes Care 30(suppl 1):S4-S41
8. Baynes J, Thorpe S (1999) Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes 48:1-9 (Pubitemid 29019345)
9. Baynes JW, Thorpe SR (2000) Glycoxidation and lipoxidation in atherogenesis. Free Radic Biol Med 28(12):1708-1716 [review] [73 refs] (Pubitemid 30628657)
10. Beisswenger PJ, Moore LL, Brinck-Johnsen T, Curphey TJ (1993) Increased collagen-linked pentosidine levels and advanced glycosylation end products in early diabetic nephropathy. J Clin Invest 92(1):212-217 (Pubitemid 23208998)
11. Beisswenger P, Lal S, Howell S, Stevens R, Siegel A, Yeo K, Randall W, Brown T, Szwergold B (1998) The role of 3-deoxyglucosone and the activity of its degradative pathways in the etiology of diabetic microvascular disease. In: O'Brien J, Nursten H, Crabbe M, Ames J (eds) The maillard reaction in foods and medicine. Royal Society of Chemistry, Cambridge, pp 298-303
12. Beisswenger P, Howell S, Touchette A, Lal S, Szwergold B (1999) Metformin reduces systemic methylglyoxal levels in type 2 diabetes. Diabetes 48:198-202 (Pubitemid 29019373)
13. Beisswenger P, Howell S, O'Dell R, Wood M, Touchette A, Szwergold B (2001) Alpha dicarbonyls increase in the postprandial period and reflect the degree of hyperglycemia. Diabetes Care 24:726-732 (Pubitemid 32888855)
14. Beisswenger P, Drummond K, Nelson R, Howell S, Szwergold B, Mauer M (2005) Susceptibility to diabetic nephropathy is related to dicarbonyl and oxidative stress. Diabetes 54:3274-3281 (Pubitemid 43334385)
15. Beisswenger P, Howell S, Szwergold B, Rich S, Russell G, Kim Y, Mauer M (2008) Progression of diabetic nephropathy is predicted by increased oxidative stress and decreased deglycation. Diabetologia 51(Suppl 1):S24
16. Borch-Johnsen K, Norgaard K, Hommel E, Mathiesen ER, Jensen JS, Deckert T, Parving HH (1992) Is diabetic nephropathy an inherited complication? Kidney Int 41(4):719-722
17. Brownlee M (1992) Glycation products and the pathogenesis of diabetic complications. Diabetes Care 15(12):1835-1843
18. Brownlee M (2001) Biochemistry and molecular cell biology of diabetic complications. Nature 414(6865):813-820 (Pubitemid 34000785)
19. Brownlee M (2005) The pathobiology of diabetic complications: a unifying mechanism. Diabetes 54(6):1615-1625 (Pubitemid 40770750)
20. Bucala R, Cerami A (1992) Advanced glycosylation: chemistry, biology, and implications for diabetes and aging. Adv Pharm 23:1-34
21. Bunn HF, Higgins PJ (1981) Reaction of monosaccharides with proteins. Possible evolutionary significance. Science 213:222-224 (Pubitemid 11060569)
22. Caramori ML, Kim Y, Huang C, Fish AJ, Rich SS, Miller ME, Russell G, Mauer M (2002) Cellular basis of diabetic nephropathy: 1. Study design, renal structural-functional relationships in patients with long-standing type 1 diabetes. Diabetes 51(2):506-513 (Pubitemid 34764810)
23. [erratum appears in diabetes apr;51(4):1294]
24. Cefalu WT (2008) Glycemic targets and cardiovascular disease. N Engl J Med 358(24):2633-2635 (Pubitemid 351831366)
25. Ceriello A, Morocutti A, Mercuri F, Quagliaro L, Moro M, Damante G, Viberti GC (2000) Defective intracellular antioxidant enzyme production in type 1 diabetic patients with nephropathy. Diabetes 49(12):2170-2177
26. Ceriello A, Hanefeld M, Leiter L, Monnier L, Moses A, Owens D, Tajima N, Tuomilehto J (2004) Postprandial glucose regulation and diabetic complications. Arch Intern Med 164(19):2090-2095 [review] [58 refs] (Pubitemid 39410797)
27. DCCT/EDIC Complications Research G (2002) Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. Jama 287(19):2563-2569
28. DCCT Research Group (1995) The relationship of glycemic exposure (hba1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes 44(8):968-983
29. DCCT Research Group (1997) Clustering of long-term complications in families with diabetes in the diabetes control and complications trial. Diabetes 46:1829-1839
30. Degenhardt TP, Thorpe SR, Baynes JW (1998) Chemical modification of proteins by methylglyoxal. Cell Mol Biol 44(7):1139-1145
31. Dluhy RG, McMahon GT (2008) Intensive glycemic control in the accord and advance trials. N Engl J Med 358(24):2630-2633 (Pubitemid 351831365)
32. Drummond K, Mauer M, International Diabetic Nephropathy Study G (2002) The early natural history of nephropathy in type 1 diabetes: II. Early renal structural changes in type 1 diabetes. Diabetes 51(5):1580-1587 (Pubitemid 34826628)
33. Drummond KN, Kramer MS, Suissa S, Levy-Marchal C, Dell'Aniello S, Sinaiko A, Mauer M, International Diabetic Nephropathy Study G (2003) Effects of duration and age at onset of type 1 diabetes on preclinical manifestations of nephropathy. Diabetes 52(7):1818-1824 (Pubitemid 36792475)
34. Du X, Matsumura T, Edelstein D, Rossetti L, Zsengeller Z, Szabo C, Brownlee M (2003) Inhibition of gapdh activity by poly(adpribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells.[see comment]. J Clin Invest 112(7):1049-1057 (Pubitemid 38056320)
35. Dyer DG, Dunn JA, Thorpe SR, Bailie KE, Lyons TJ, McCance DR, Baynes JW (1993) Accumulation of maillard reaction products in skin collagen in diabetes and aging. J Clin Invest 91(6): 2463-2469 (Pubitemid 23182497)
36. Ejaz S, Chekarova I, Ejaz A, Sohail A, Lim CW (2008) Importance of pericytes and mechanisms of pericyte loss during diabetes retinopathy. Diabetes Obes Metab 10(1):53-63 (Pubitemid 350302431)
37. ETDRS (1991) Early photocoagulation for diabetic retinopathy. Etdrs report number 9. Early treatment diabetic retinopathy study research group. Ophthalmology 98(Suppl 5):766-785
38. Fioretto P, Steffes MW, Barbosa J, Rich SS, Miller ME, Mauer M (1999) Is diabetic nephropathy inherited? Studies of glomerular structure in type 1 diabetic sibling pairs. Diabetes 48(4):865-869 (Pubitemid 29153088)
39. Fong DS, Ferris FL 3rd, Davis MD, Chew EY (1999) Causes of severe visual loss in the early treatment diabetic retinopathy study: Etdrs report no. 24. Early treatment diabetic retinopathy study research group. Am J Ophthalmol 127(2):137-141 (Pubitemid 29072552)
40. Frank RN (2004) Diabetic retinopathy. N Engl J Med 350(1):48-58 [see comment] [review] [94 refs] (Pubitemid 38032183)
41. Gaut JP, Byun J, Tran HD, Heinecke JW (2002) Artifact-free quantification of free 3-chlorotyrosine, 3-bromotyrosine, 3-nitrotyrosine in human plasma by electron capture-negative chemical ionization gas chromatography mass spectrometry, liquid chromatography-electrospray ionization tandem mass spectrometry. Anal Biochem 300(2):252-259 (Pubitemid 34093701)
42. [erratum appears in anal biochem 2002 may 15;304(2):275]
43. Geibauf A, Van Wickern B, Simat T, Steinhart H, Esterbauer H (1996) Formation of n-formylkynurenine suggests the involvement of apolipoprotein b-100 centered tryptophan radicals in the initiation of ldl lipid peroxidation. FEBS Lett 389:136-140 (Pubitemid 26226486)
44. Goldberg AL (2003) Protein degradation and protection against misfolded or damaged proteins. Nature 426(6968):895-899 [review] [45 refs] (Pubitemid 38056882)
45. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M (1998) Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339(4):229-234 [comment] (Pubitemid 28350165)
46. Hammes HP, Lin J, Renner O, Shani M, Lundqvist A, Betsholtz C, Brownlee M, Deutsch U (2002) Pericytes and the pathogenesis of diabetic retinopathy. Diabetes 51(10):3107-3112
47. Hammes H, Xueliang D, Edelstein D, Taguchi T, Matsumura T, Q J, Lin J, Bierhaus A, Nawroth P, Hannak D, Neumaier M, Berfield R, Giardina I, Brownlee M (2003) Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med 9:294-299 (Pubitemid 36362784)
48. Hink U, Li H, Mollnau H, Oelze M, Matheis E, Hartmann M, Skatchkov M, Thaiss F, Stahl RA, Warnholtz A, Meinertz T, Griendling K, Harrison DG, Forstermann U, Munzel T (2001) Mechanisms underlying endothelial dysfunction in diabetes mellitus. Circ Res 88(2):2
49. Hirata C, Nakano K, Nakamura N, Kitagawa Y, Shigeta H, Hasegawa G, Ogata M, Ikeda T, Sawa H, Nakamura K, Ienaga K, Obayashi H, Kondo M (1997) Advanced glycation end products induce expression of vascular endothelial growth factor by retinal muller cells. Biochem Biophys Res Commun 236:712-715 (Pubitemid 27384695)
50. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA (2008) 10- year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359(15):1577-1589 [see comment]
51. Huang C, Kim Y, Caramori ML, Fish AJ, Rich SS, Miller ME, Russell GB, Mauer M (2002) Cellular basis of diabetic nephropathy: II. The transforming growth factor-beta system and diabetic nephropathy lesions in type 1 diabetes. Diabetes 51(12):3577-3581 (Pubitemid 35403466)
52. Hunt KJ, Williams K, Hazuda HP, Stern MP, Haffner SM (2007) The metabolic syndrome and the impact of diabetes on coronary heart disease mortality in women and men: the san antonio heart study. Ann Epidemiol 17(11):870-877 (Pubitemid 47588953)
53. Kalea AZ, Schmidt AM, Hudson BI (2009) Rage: a novel biological and genetic marker for vascular disease. Clin Sci 116(8): 621-637
54. Koschinsky T, He CJ, Mitsuhashi T, Bucala R, Liu C, Buenting C, Heitmann K, Vlassara H (1997) Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy. Proc Natl Acad Sci USA 94(12): 6474-6479 (Pubitemid 27270709)
55. Krolewski AJ, Warram JH, Kahn R, Kahn LI, Kahn CR (1987) Epidemiologic approach to the etiology of type I diabetes mellitus and its complications. New Eng J Med 18:267-273
56. Lachin JM, Genuth S, Nathan DM, Rutledge BN (2007) The hemoglobin glycation index is not an independent predictor of the risk of microvascular complications in the diabetes control and complications trial. Diabetes 56(7):1913-1921 [see comment] (Pubitemid 47025457)
57. Mauer M, Zinman B, Gardiner R, Drummond K, Suissa S, Donnelly S, Strand T, Kramer M, Klein R, Sinaiko A (2002) Ace-i and arbs in early diabetic nephropathy. J Renin Angiotensin Aldosterone Syst 3:262-269 (Pubitemid 36181996)
58. Mauer M, Zinman B, Gardiner R, Suissa S, Sinaiko A, Strand T, Drummond K, Donnelly S, Goodyer P, Gubler MC, Klein R (2009) Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med 361(1):40-51
59. Miyata T, Fu MX, Kurokawa K, de Strihou C, Thorpe SR, Baynes JW (1998) Autoxidation products of both carbohydrates and lipids are increased in uremic plasma: is there oxidative stress in uremia? Kidney Int 54(4):1290-1295 (Pubitemid 28449917)
60. Monnier VM (1989) The maillard reaction in aging, diabetes and nutrition. Prog in Clin and Biol Res 304:1-22
61. Monnier L, Colette C (2006) Contributions of fasting and postprandial glucose to hemoglobin a1c. Endocr Pract 1:42-46 [review] [20 refs] (Pubitemid 44963610)
62. Monnier VM, Sell DR, Genuth S (2005) Glycation products as markers and predictors of the progression of diabetic complications. Ann N Y Acad Sci 1043:567-581 [review] [78 refs] (Pubitemid 41123947)
63. Monnier VM, Sell DR, Dai Z, Nemet I, Collard F, Zhang J (2008) The role of the amadori product in the complications of diabetes. Ann N Y Acad Sci 1126:81-88 (Pubitemid 351589314)
64. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, Raskin P, Zinman B, Diabetes C, Complications Trial/Epidemiology of Diabetes I, Complications Study Research G (2005) Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. New Engl J Med 353(25):2643-2653 [see comment] (Pubitemid 41817713)
65. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B (2008) Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: Update regarding thiazolidinediones: a consensus statement from the american diabetes association and the european association for the study of diabetes. Diabetes Care 31(1):173-175
66. Nishikawa T, Edelstein D, Du X, Yamagishi S, Matsumura T, Kaneda Y, Yorek M, Beebe D, Oates P, Hammes H, Giardino I, Brownlee M (2000) Normalizing mitochondrial superoxide production blocks three pathways of hyperglycemic damage. Nature 404:787-790 (Pubitemid 30212409)
67. Niwa T (2008) Biomarker discovery for kidney diseases by mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 870(2):148-153 (Pubitemid 351992935)
68. Perkins BA, Krolewski AS (2009) Early nephropathy in type 1 diabetes: the importance of early renal function decline. Curr Opin Nephrol Hypertens 18(3):233-240
69. Pettitt D, Saad M, Bennett P, Nelson R, Knowler W (1990) Familial predisposition to renal disease in two generations of pima indians with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 33(7):438-443 (Pubitemid 20220945)
70. Prager TC, Wilson DJ, Avery GD (1981) Vitreous fluorophotometry: identification of sources of variability. Invest Ophthalmol Vis Sci 21:854-864 (Pubitemid 12250382)
71. Rodbard HW, Trence DL, Mechanick JI (2008) Should the recommendation of the american association of clinical endocrinologists for a hemoglobin a1c target of 6.5% be modified? A critical reappraisal of recent studies of intensive glycemic control. Endocr Pract 14(6):791-795
72. Rohlfing CL, Wiedmeyer HM, Little RR, England JD, Tennill A, Goldstein DE (2002) Defining the relationship between plasma glucose and hba(1c): Analysis of glucose profiles and hba(1c) in the diabetes control and complications trial. Diabetes Care 25(2):275-278 (Pubitemid 41079621)
73. Rosario RF, Prabhakar S (2006) Lipids and diabetic nephropathy. Curr Diab Rep 6(6):455-462 [review] [58 refs] (Pubitemid 44896405)
74. Saaddine JB, Honeycutt AA, Narayan KM, Zhang X, Klein R, Boyle JP (2008) Projection of diabetic retinopathy and other major eye diseases among people with diabetes mellitus: United states, 2005-2050. Arch Ophthalmol 126(12):1740-1747
75. Seaquist ER, Goetz FC, Rich S, Barbosa J (1989) Familial clustering of diabetic kidney disease: evidence for genetic susceptibility to diabetic nephropathy. N Engl J Med 320:1161-1165 (Pubitemid 19124296)
76. Sell DR, Annunziata L, Monnier VM (1991) Relationship between pentosidine and the complications of long-standing type I diabetes. Diabetes 40(Suppl I):302A
77. Sell DR, Strauch CM, Shen W, Monnier VM (2007) 2-aminoadipic acid is a marker of protein carbonyl oxidation in the aging human skin: effects of diabetes, renal failure and sepsis. Biochem J 404(2):269-277 (Pubitemid 46849598)
78. Shaw JE, Sicree RA, Zimmet PZ (2010) Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 87:4-14
79. Soriano FG, Virag L, Szabo C (2001) Diabetic endothelial dysfunction: Role of reactive oxygen and nitrogen species production and poly(adp-ribose) polymerase activation. J Mol Med 79(8):437-448 [review] [92 refs] (Pubitemid 32757469)
80. Thornalley PJ (1999) Clinical significance of glycation. Clin Lab 45:263-273
81. Thornalley PJ, Battah S, Ahmed N, Karachalias N, Agalou S, Babaei-Jadidi R, Dawnay A (2003) Quantitative screening of advanced glycation end products in cellular and extracellular proteins by tandem mass spectrometry. Biochem J 375(Pt 3):581-592 (Pubitemid 37433506)
82. Turner RC, Millns H, Neil HA, Stratton IM, Manley SE, Matthews DR, Holman RR (1998) Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United kingdom prospective diabetes study. Bmj 316(7134):823-828 (ukpds: 23) [comment] (Pubitemid 28112428)
83. Williams M (2010) Diabetic chronic kidney disease/end-stage renal disease: a progress report. Semin Dial 23:129-133
84. Wolff SP, Dean RT (1987) Glucose autoxidation and protein modification. Biochem J 245:243-250
85. Yan SF, Ramasamy R, Schmidt AM (2009) The receptor for advanced glycation end products (rage) and cardiovascular disease. Expert Rev Mol Med 11:e9
86. Yu Y, Thorpe SR, Jenkins AJ, Shaw JN, Sochaski MA, McGee D, Aston CE, Orchard TJ, Silvers N, Peng YG, McKnight JA, Baynes JW, Lyons TJ, The DERG (2006) Advanced glycation end-products and methionine sulphoxide in skin collagen of patients with type 1 diabetes. Diabetologia 49(10):2488-2498 (Pubitemid 44359112)